WallStreetZenWallStreetZen

NASDAQ: ALLR
Allarity Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Should I buy or sell ALLR stock?

Based on 1 analyst offering ratings for Allarity Therapeutics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ALLR stock forecasts and price targets.

ALLR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Ladenburg Thalmann
Bottom 4%
4
HoldDowngradesN/AN/A2022-08-23

1 of 1

Forecast return on equity

Is ALLR forecast to generate an efficient return?

Forecast return on assets

Is ALLR forecast to generate an efficient return on assets?
Company
-187.71%
Industry
-5.95%
ALLR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALLR earnings per share forecast

What is ALLR's earnings per share in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.91

ALLR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALLR$0.14N/AN/AHold
SLRX$1.90$5.00+163.16%Strong Buy
NRBO$0.66$6.00+809.09%Strong Buy
RNAZ$0.34$6.00+1,669.91%Buy
IMV$0.51$65.00+12,645.10%Buy
View Top Biotech Stocks

Allarity Therapeutics Stock Forecast FAQ

Is Allarity Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ALLR) stock is to Hold ALLR stock.

Out of 1 analyst, 0 (0%) are recommending ALLR as a Strong Buy, 0 (0%) are recommending ALLR as a Buy, 1 (100%) are recommending ALLR as a Hold, 0 (0%) are recommending ALLR as a Sell, and 0 (0%) are recommending ALLR as a Strong Sell.

If you're new to stock investing, here's how to buy Allarity Therapeutics stock.

What is ALLR's Earnings Per Share (EPS) forecast for 2023-2023?

(NASDAQ: ALLR) Allarity Therapeutics's current Earnings Per Share (EPS) is -$2.21. In 2023, ALLR's EPS is forecast to hit -$0.91 (min: -$0.91, max: -$0.91).

What is ALLR's forecast return on assets (ROA) for 2023-2023?

(NASDAQ: ALLR) forecast ROA is -187.71%, which is lower than the forecast US Biotechnology industry average of -5.95%.

What is ALLR's earnings growth forecast for 2023-2023?

(NASDAQ: ALLR) Allarity Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Allarity Therapeutics's earnings in 2023 is -$21,051,000.

In 2023, ALLR is forecast to generate -$27,300,000 in earnings, with the lowest earnings forecast at -$27,300,000 and the highest earnings forecast at -$27,300,000.

What is ALLR's forecast return on equity (ROE) for 2023-2023?

(NASDAQ: ALLR) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.